Pheno Therapeutics buys rights to potential remyelination drug


Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.  

“Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This license allows us to accelerate a promising drug target towards clinical development,” said Fraser Murray, Chief Executive Officer of Pheno Therapeutics. 

“There is significant opportunity for Pheno Therapeutics to fast-track this program towards clinical proof-of-concept studies and potentially deliver transformational drugs for the treatment of demyelination diseases.” 

“We are confident that Pheno Therapeutics, with its expertise in phenotypic screening, stem cell technology and myelin biology, will develop this preclinical program to its full potential,” added Dhaval Patel, Executive Vice President and UCB’s Chief Scientific Officer. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free